Back to results
US 12,577,278 B2Granted
KRAS G12V mutant binds to JAK1, inhibitors, pharmaceutical compositions, and methods related thereto
AssigneeEmory University
InventorsHaian Fu, Xiulei Mo, Cong Tang
Life of this patent
Estimating the term…
Abstract
This disclosure relates to the discovery that a G12V mutant of KRAS (hereinafter KRAS G12V) binds to JAK1, i.e., the existence of a KRAS G12V and JAK1 binding interaction. In certain embodiments, this disclosure relates to methods of disrupting the KRAS G12V and JAK1 interaction reversing KRAS G12V induced immune escape by cancer cells utilizing agents that prevent the binding of JAK1 to KRAS G12V.
Claims11
A method of treating a cancer with a KRAS G12V mutation comprising administering an effective amount of a peptide consisting of the amino acid sequence MDYKDDEG (SEQ ID NO:
- 1) or ADYKDDEG (SEQ ID NO:
- 2) to a subject in need thereof.
Dependencies are inferred from the claim text.